- $1.30bn
- $1.82bn
- $775.85m
- 91
- 37
- 94
- 86
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 762 | 784 | 709 | 688 | 776 |
Cost of Revenue | |||||
Gross Profit | 241 | 246 | 237 | 221 | 271 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 705 | 860 | 659 | 757 | 727 |
Operating Profit | 57.1 | -75.9 | 50.4 | -69.3 | 49.1 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 40.6 | -78.2 | 60.5 | -65.9 | 10.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | 56.5 | -70.4 | 43.7 | -48.6 | 7.95 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 210 | -69.7 | 43.7 | -48.6 | 7.95 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 210 | -69.7 | 43.7 | -48.6 | 7.95 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.16 | 0.309 | 1.75 | 0.32 | 0.411 |
Dividends per Share |